Zymeworks Inc. (NYSE:ZYME - Get Free Report) Director Ecor1 Capital, Llc purchased 58,306 shares of the business's stock in a transaction on Wednesday, March 19th. The shares were purchased at an average cost of $12.64 per share, for a total transaction of $736,987.84. Following the transaction, the director now directly owns 17,030,604 shares of the company's stock, valued at approximately $215,266,834.56. The trade was a 0.34 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Ecor1 Capital, Llc also recently made the following trade(s):
- On Monday, March 17th, Ecor1 Capital, Llc purchased 56,277 shares of Zymeworks stock. The stock was acquired at an average cost of $12.23 per share, for a total transaction of $688,267.71.
- On Thursday, March 13th, Ecor1 Capital, Llc acquired 468,356 shares of Zymeworks stock. The stock was bought at an average price of $12.48 per share, with a total value of $5,845,082.88.
- On Tuesday, March 11th, Ecor1 Capital, Llc bought 320,690 shares of Zymeworks stock. The shares were bought at an average cost of $11.49 per share, for a total transaction of $3,684,728.10.
- On Friday, January 17th, Ecor1 Capital, Llc purchased 19,748 shares of Zymeworks stock. The stock was bought at an average cost of $13.87 per share, with a total value of $273,904.76.
- On Wednesday, January 15th, Ecor1 Capital, Llc bought 39,029 shares of Zymeworks stock. The stock was purchased at an average cost of $14.01 per share, with a total value of $546,796.29.
- On Monday, January 13th, Ecor1 Capital, Llc purchased 74,125 shares of Zymeworks stock. The stock was purchased at an average price of $13.39 per share, for a total transaction of $992,533.75.
- On Friday, January 10th, Ecor1 Capital, Llc acquired 204,098 shares of Zymeworks stock. The stock was purchased at an average cost of $13.13 per share, with a total value of $2,679,806.74.
- On Wednesday, January 8th, Ecor1 Capital, Llc bought 21,021 shares of Zymeworks stock. The shares were purchased at an average cost of $14.07 per share, for a total transaction of $295,765.47.
- On Thursday, January 2nd, Ecor1 Capital, Llc purchased 157,880 shares of Zymeworks stock. The stock was acquired at an average cost of $14.78 per share, with a total value of $2,333,466.40.
- On Monday, December 30th, Ecor1 Capital, Llc acquired 58,988 shares of Zymeworks stock. The shares were acquired at an average price of $14.47 per share, for a total transaction of $853,556.36.
Zymeworks Stock Down 1.6 %
ZYME stock traded down $0.21 during midday trading on Friday, hitting $12.72. The company's stock had a trading volume of 800,233 shares, compared to its average volume of 475,928. The stock has a market cap of $885.02 million, a price-to-earnings ratio of -8.48 and a beta of 1.13. The stock's 50-day moving average price is $13.72 and its 200 day moving average price is $13.70. Zymeworks Inc. has a 1 year low of $7.97 and a 1 year high of $17.70.
Institutional Investors Weigh In On Zymeworks
A number of hedge funds have recently made changes to their positions in ZYME. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its holdings in Zymeworks by 0.8% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,945,491 shares of the company's stock worth $24,416,000 after buying an additional 14,604 shares during the last quarter. Deutsche Bank AG grew its position in shares of Zymeworks by 1.2% during the 4th quarter. Deutsche Bank AG now owns 1,546,772 shares of the company's stock valued at $22,645,000 after acquiring an additional 17,849 shares during the period. State Street Corp increased its stake in shares of Zymeworks by 6.1% during the 3rd quarter. State Street Corp now owns 1,171,777 shares of the company's stock worth $14,706,000 after purchasing an additional 67,401 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Zymeworks by 14.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 972,742 shares of the company's stock worth $14,240,000 after purchasing an additional 123,240 shares during the period. Finally, Bridgeway Capital Management LLC lifted its stake in Zymeworks by 2.3% in the fourth quarter. Bridgeway Capital Management LLC now owns 759,653 shares of the company's stock valued at $11,121,000 after purchasing an additional 17,092 shares during the last quarter. 92.89% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research firms have recently commented on ZYME. Wells Fargo & Company boosted their target price on shares of Zymeworks from $12.00 to $14.00 and gave the stock an "equal weight" rating in a research report on Thursday, December 19th. Lifesci Capital started coverage on Zymeworks in a research note on Tuesday, March 11th. They issued an "outperform" rating and a $30.00 price objective for the company. JPMorgan Chase & Co. raised Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 target price on the stock in a research report on Monday, December 16th. Citigroup increased their price target on Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a research report on Friday, March 7th. Finally, HC Wainwright raised their price objective on Zymeworks from $12.00 to $13.00 and gave the company a "neutral" rating in a research note on Monday, March 10th. Two equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $21.00.
Read Our Latest Stock Analysis on Zymeworks
About Zymeworks
(
Get Free Report)
Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.
Read More
Before you consider Zymeworks, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zymeworks wasn't on the list.
While Zymeworks currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
